Development and Commercialization Efforts. As set forth therein, Opus will, and will cause its Affiliates and Product Licensees to meet the level of diligence required with respect to the Development and Commercialization of IC-200 Product as required pursuant to the IC-200 License Agreement. Opus will deliver to Iveric all reports owed to the Institution Licensors under the Assigned License Agreements. Section 5.1.2 sets forth ▇▇▇▇▇▇’s sole remedy for breach of this Section 5.1.1.
Appears in 2 contracts
Sources: Asset Purchase Agreement (Opus Genetics, Inc.), Asset Purchase Agreement (IVERIC Bio, Inc.)